Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$7.90	$7.50	$5.90 ▼ $29.61	$567.52M	2.38	1.84 million shs	925,531 shs
BDTX Black Diamond Therapeutics	$2.88 +2.9%	$2.76	$1.20 ▼ $6.33	$156.57M	2.93	826,905 shs	678,683 shs
IOVA Iovance Biotherapeutics	$2.21 +0.9%	$2.36	$1.64 ▼ $12.51	$806.93M	0.82	14.25 million shs	7.30 million shs
TBPH Theravance Biopharma	$13.73 -0.8%	$11.99	$7.88 ▼ $14.55	$699.02M	0.05	488,251 shs	717,025 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	+2.20%	+4.77%	+6.47%	+13.67%	-69.80%
BDTX Black Diamond Therapeutics	+1.82%	-3.45%	+8.11%	+10.24%	-54.10%
IOVA Iovance Biotherapeutics	-1.79%	-10.61%	-18.28%	+19.67%	-81.22%
TBPH Theravance Biopharma	-0.29%	+0.29%	+26.97%	+25.70%	+67.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARVN Arvinas	2.7624 of 5 stars	3.3	1.0	0.0	3.1	2.5	1.3
BDTX Black Diamond Therapeutics	3.2888 of 5 stars	3.6	1.0	0.0	3.7	1.7	1.9
IOVA Iovance Biotherapeutics	4.2927 of 5 stars	4.2	1.0	4.2	2.3	2.5	0.6
TBPH Theravance Biopharma	3.6314 of 5 stars	3.8	2.0	0.0	2.9	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.55	Moderate Buy	$19.76	150.17% Upside
BDTX Black Diamond Therapeutics	3.17	Buy	$12.40	330.56% Upside
IOVA Iovance Biotherapeutics	2.36	Hold	$11.90	438.46% Upside
TBPH Theravance Biopharma	3.50	Strong Buy	$21.33	55.38% Upside

Current Analyst Ratings Breakdown

Latest BDTX, ARVN, IOVA, and TBPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	IOVA Iovance Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/15/2025	TBPH Theravance Biopharma	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/12/2025	IOVA Iovance Biotherapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/11/2025	BDTX Black Diamond Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2025	BDTX Black Diamond Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
8/8/2025	IOVA Iovance Biotherapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$18.00 ➝ $14.00
8/8/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $20.00
8/7/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $18.00
8/7/2025	ARVN Arvinas	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$19.00 ➝ $16.00
8/7/2025	ARVN Arvinas	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
7/23/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00

(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$263.40M	2.20	N/A	N/A	$8.30 per share	0.95
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	$2.33 per share	N/A
IOVA Iovance Biotherapeutics	$164.07M	4.87	N/A	N/A	$1.93 per share	1.15
TBPH Theravance Biopharma	$64.38M	10.74	N/A	N/A	$4.46 per share	3.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$198.90M	-$1.01	N/A	N/A	N/A	-19.47%	-12.01%	-6.97%	10/29/2025 (Estimated)
BDTX Black Diamond Therapeutics	-$69.68M	$0.23	12.52	N/A	N/A	N/A	12.70%	9.58%	11/4/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$372.18M	-$1.23	N/A	N/A	N/A	-161.44%	-52.87%	-41.31%	11/6/2025 (Estimated)
TBPH Theravance Biopharma	-$56.42M	$0.24	57.21	39.23	N/A	16.88%	6.93%	3.52%	11/11/2025 (Estimated)

Latest BDTX, ARVN, IOVA, and TBPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	BDTX Black Diamond Therapeutics	-$0.25	-$0.19	+$0.06	-$0.19	N/A	N/A
8/7/2025	Q2 2025	IOVA Iovance Biotherapeutics	-$0.29	-$0.33	-$0.04	-$0.33	$67.14 million	$59.95 million
8/6/2025	Q2 2025	ARVN Arvinas	-$0.87	-$0.84	+$0.03	-$0.84	$34.42 million	$22.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	5.64	5.64
BDTX Black Diamond Therapeutics	N/A	8.73	8.73
IOVA Iovance Biotherapeutics	N/A	3.27	2.89
TBPH Theravance Biopharma	N/A	6.70	6.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
BDTX Black Diamond Therapeutics	95.47%
IOVA Iovance Biotherapeutics	77.03%
TBPH Theravance Biopharma	99.10%

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	4.73%
BDTX Black Diamond Therapeutics	5.97%
IOVA Iovance Biotherapeutics	10.30%
TBPH Theravance Biopharma	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	420	73.42 million	69.95 million	Optionable
BDTX Black Diamond Therapeutics	90	56.94 million	53.54 million	Optionable
IOVA Iovance Biotherapeutics	500	361.85 million	324.58 million	Optionable
TBPH Theravance Biopharma	110	50.36 million	46.89 million	Optionable

BDTX, ARVN, IOVA, and TBPH Headlines

Recent News About These Companies

Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 2 at 6:00 AM | prnewswire.com

Wellington Management Group LLP Sells 43,062 Shares of Theravance Biopharma, Inc. $TBPH

September 2 at 3:58 AM | marketbeat.com

Russell Investments Group Ltd. Has $429,000 Stake in Theravance Biopharma, Inc. $TBPH

September 2 at 3:49 AM | marketbeat.com

Vanguard Group Inc. Grows Stake in Theravance Biopharma, Inc. $TBPH

September 1 at 3:12 AM | marketbeat.com

Theravance Biopharma, Inc. $TBPH Shares Sold by Deutsche Bank AG

September 1 at 3:12 AM | marketbeat.com

Nuveen LLC Acquires Shares of 374,952 Theravance Biopharma, Inc. $TBPH

August 30, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above 50 Day Moving Average - Here's Why

August 28, 2025 | marketbeat.com

Theravance Biopharma, Inc.: Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic ...

August 25, 2025 | finanznachrichten.de

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple ...

August 25, 2025 | finance.yahoo.com

Theravance Biopharma completes enrollment in CYPRESS study

August 25, 2025 | msn.com

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy

August 25, 2025 | prnewswire.com

Theravance Biopharma Settles Patent Dispute with Cipla

August 20, 2025 | msn.com

Theravance Biopharma (NASDAQ:TBPH) Hits New 1-Year High - Here's What Happened

August 20, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Rating Increased to Strong-Buy at Wall Street Zen

August 17, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Stock Price Up 3.4% - Here's Why

August 16, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Sets New 1-Year High on Earnings Beat

August 14, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results

August 14, 2025 | marketbeat.com

Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

August 13, 2025 | zacks.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2025 Earnings Call Transcript

August 13, 2025 | msn.com

Theravance Biopharma Inc (TBPH) Q2 2025: Everything You Need To Know Ahead Of Earnings

August 13, 2025 | finance.yahoo.com

Theravance Biopharma reports Q2 EPS $1.08 with items, consensus (12c)

August 12, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX, ARVN, IOVA, and TBPH Company Descriptions

Arvinas NASDAQ:ARVN

$7.90 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$7.90 0.00 (0.00%)

As of 07:36 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Black Diamond Therapeutics NASDAQ:BDTX

$2.88 +0.08 (+2.86%)

Closing price 04:00 PM Eastern

Extended Trading

$2.92 +0.04 (+1.22%)

As of 07:57 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Iovance Biotherapeutics NASDAQ:IOVA

$2.21 +0.02 (+0.91%)

Closing price 04:00 PM Eastern

Extended Trading

$2.25 +0.04 (+1.76%)

As of 07:50 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Theravance Biopharma NASDAQ:TBPH

$13.73 -0.11 (-0.79%)

Closing price 04:00 PM Eastern

Extended Trading

$13.74 +0.00 (+0.04%)

As of 06:46 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time